Adial Pharmaceuticals (ADIL) Q4 2024 earnings summary

Executive summary

• Completed AD04-103 pharmacokinetics study, confirming bioavailability, dose proportionality, no food effect, and safety profile consistent with Ondansetron.

• Received FDA confirmation for 505(b)(2) bridging strategy, enabling progression to Phase 3 clinical trials.

• Initiated manufacturing of clinical supplies for Phase 3 program in 2025.

• Strengthened regulatory pathway through partnership with Boudicca Dx for companion diagnostic genetic test.

• Appointed Vinay Shah as Chief Financial Officer, bringing over 25 years of sector experience.

Financial highlights

• Cash and cash equivalents were $3.8 million as of December 31, 2024, up from $2.8 million a year earlier.

• Research and development expenses rose by $1.9 million (155%) year-over-year, mainly due to clinical trial and manufacturing costs.

• General and administrative expenses decreased by $491 thousand (9%) year-over-year, driven by lower legal and compensation costs.

• Net loss was $13.2 million for 2024, compared to $5.1 million in 2023, primarily due to non-cash inducement expense, equity method investment loss, and increased R&D spending.

• Existing cash is expected to fund operations into the second half of 2025.

Outlook and guidance

• Positioned to initiate Phase 3 clinical trials for AD04 in 2025.

• Focus remains on advancing AD04 efficiently to address addiction treatment needs.

• Cash runway projected into the second half of 2025 based on current development plans.